236
# Calculating effective dose (ED) values
# first column: the estimates ED50, ED80, and
ED90
# second column: the estimated standard errors
ED(DR.1, c(50, 80, 90))
EDout = ED(DR.1, c(50))
# Labelling of x axis, compound name & unit
DRxlab = "EGFld [ng/ml]" #or "Lapatinib [μM]
& 10 ng/ml EGFld"
# Plotting graph with y axis from 0 to 100%
activity
plot(DR.1, broken = FALSE, type = c("all")
,ylab = "activity[%]", xlab = DRxlab, log
= "x", xt = c(0.001, 0.01, 0.1, 1, 10,
100), ylim = c(0, 115), legend = FALSE,
bty = "l", sub = paste("EC50: ",round(EDo
ut[1,1],4),"μM",sep=" ")) #adjust EC/IC50
and concentration
# Adding error bars as sem
for (i in 1:dim(drc)[1]){
segments(drc[i,2],drc[i,1]-drc[i,3],drc[i,2],
drc[i,1]+drc[i,3],col="black")
}
Acknowledgment
This work was supported by the Ludwig Maximilian University of
Munich and the DFG grant WE 5683/1-1 to M.C.W.
References
1. McNeill H, Woodgett JR (2010) When pathways collide: collaboration and connivance
among signalling proteins in development. Nat
Rev Mol Cell Biol 11:404–13. doi:10.1038/
nrm2902.
2. Heng BC, Aubel D, Fussenegger M (2013) An
overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology
of various human diseases. Biotechnol Adv
31(8):1676–94.
doi:10.1016/j.biotechadv.
2013.08.017.
3. Lemmon MA, Schlessinger J. Cell signaling by
receptor tyrosine kinases. Cell. 2010;141:1117–
34. doi:10.1016/j.cell.2010.06.011.
4. Billingsley ML (2008) Druggable targets and
targeted drugs: enhancing the development of
new therapeutics. Pharmacology 82:239–244.
doi:10.1159/000157624
5. Michnick SW, Ear PH, Manderson EN, Remy
I, Stefan E (2007) Universal strategies in
research and drug discovery based on proteinfragment complementation assays. Nat Rev
Drug Discov 6:569–582. doi:10.1038/
nrd2311
6. Wehr MC, Rossner MJ (2016) Split protein
biosensor assays in molecular pharmacological
studies. Drug Discov Today 21:415–29.
doi:10.1016/j.drudis.2015.11.004.
Jan P. Wintgens et al.
# Calculating effective dose (ED) values
# first column: the estimates ED50, ED80, and
ED90
# second column: the estimated standard errors
ED(DR.1, c(50, 80, 90))
EDout = ED(DR.1, c(50))
# Labelling of x axis, compound name & unit
DRxlab = "EGFld [ng/ml]" #or "Lapatinib [μM]
& 10 ng/ml EGFld"
# Plotting graph with y axis from 0 to 100%
activity
plot(DR.1, broken = FALSE, type = c("all")
,ylab = "activity[%]", xlab = DRxlab, log
= "x", xt = c(0.001, 0.01, 0.1, 1, 10,
100), ylim = c(0, 115), legend = FALSE,
bty = "l", sub = paste("EC50: ",round(EDo
ut[1,1],4),"μM",sep=" ")) #adjust EC/IC50
and concentration
# Adding error bars as sem
for (i in 1:dim(drc)[1]){
segments(drc[i,2],drc[i,1]-drc[i,3],drc[i,2],
drc[i,1]+drc[i,3],col="black")
}
Acknowledgment
This work was supported by the Ludwig Maximilian University of
Munich and the DFG grant WE 5683/1-1 to M.C.W.
References
1. McNeill H, Woodgett JR (2010) When pathways collide: collaboration and connivance
among signalling proteins in development. Nat
Rev Mol Cell Biol 11:404–13. doi:10.1038/
nrm2902.
2. Heng BC, Aubel D, Fussenegger M (2013) An
overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology
of various human diseases. Biotechnol Adv
31(8):1676–94.
doi:10.1016/j.biotechadv.
2013.08.017.
3. Lemmon MA, Schlessinger J. Cell signaling by
receptor tyrosine kinases. Cell. 2010;141:1117–
34. doi:10.1016/j.cell.2010.06.011.
4. Billingsley ML (2008) Druggable targets and
targeted drugs: enhancing the development of
new therapeutics. Pharmacology 82:239–244.
doi:10.1159/000157624
5. Michnick SW, Ear PH, Manderson EN, Remy
I, Stefan E (2007) Universal strategies in
research and drug discovery based on proteinfragment complementation assays. Nat Rev
Drug Discov 6:569–582. doi:10.1038/
nrd2311
6. Wehr MC, Rossner MJ (2016) Split protein
biosensor assays in molecular pharmacological
studies. Drug Discov Today 21:415–29.
doi:10.1016/j.drudis.2015.11.004.
Jan P. Wintgens et al.